Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue

January 12, 2026
Press release - Regulatory
  • Circio is intending to raise up to NOK 50 million in a rights issue, with strong support from several of its main shareholders
  • Existing and new shareholders can subscribe in the rights issue during the period 15-29 January 2026
  • In the webcast, CEO Dr. Erik D Wiklund will provide an overview of the transaction structure and timelines, as well as a general corporate update

Oslo, Norway, 12 January 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, invites to a live webcast at 10:00am CET on Thursday 15 January 2026.

On 8 December 2025, Circio announced a proposed rights issue of up NOK 50 million with strong support from several of its main shareholders. The rights issue is 88% covered by pre-subscriptions and guarantee commitments. On 12 January 2026, the extraordinary general meeting of Circio approved the proposed transaction, and investors can subscribe in the rights issue during the period 15-29 January 2026.

In the webcast, CEO Dr. Erik D Wiklund will provide information and timelines for the rights issue, as well as a general corporate update. The webcast will be held in Norwegian. Questions can be submitted in advance by email to: erik.wiklund@circio.com or directly in the live webcast.

Time: 10:00 CET on Thursday 15 January 2026

Click here to access Teams webcast
Meeting ID: 364 333 177 801 32
Passcode: PM96YW9U

A recording of the webcast will be made available on the Circio webpage

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.